Professor, Medicine, Boston University School of Medicine
Hematology
Dr. David C. Seldin, MD
|
|
Give Review
David Seldin practices Hematology. He graduated from Harvard Medical School. Harvard Medical School is one of the top medical schools in the US. Harvard Medical School has a rank of 1 in research and a 12 in primary care He received awards:"Elected Member" and "Super Doctor". David C. Seldin is a published MD. He has 85 papers published. The most current publication "First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction." Dr. David C. Seldin is registered with Medicare.
Publications
- Clinical presentation and treatment responses in IgM-related AL amyloidosis.
- Serum free light chain trends between orthotopic heart transplantation and auto-SCT in patients with AL amyloidosis.
- Cooperative Stabilization of Transthyretin by Clusterin and Diflunisal.
- Genetic variation of the transthyretin gene in wild-type transthyretin amyloidosis (ATTRwt).
- Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity.
- Lymphadenopathy as a manifestation of amyloidosis: a case series.
- Hospital admissions following outpatient administration of high-dose melphalan and autologous SCT for AL amyloidosis.
- Plerixafor-augmented peripheral blood stem cell mobilization in AL amyloidosis with cardiac involvement: a case series.
- Single agent lenalidomide three times a week induces hematologic responses in AL amyloidosis patients on dialysis.
- Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement.
- Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial.
- Predictors of Survival to Orthotopic Heart Transplant in Patients with Light Chain Amyloidosis.
- Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity.
- Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish.
- New hematologic response criteria predict survival in patients with immunoglobulin light chain amyloidosis treated with high-dose melphalan and autologous stem-cell tr...
- Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: Analysis of SWOG trial S0115.
- Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial.
- Risk of second primary malignancy in patients with AL amyloidosis treated with lenalidomide.
- A solitary Mediastinal mass due to localized AL amyloidosis: case report and review of the literature.
- Amyloidosis of the gastrointestinal Tract: a 13-year, single-center, referral experience.
- Microbiologically documented infections in patients undergoing high-dose melphalan and autologous stem cell transplantation for the treatment of light chain amyloidosis.
- Epithelial-to-Mesenchymal Transition Induced by TGF-ò1 Is Mediated by Blimp-1-Dependent Repression of BMP-5.
- Expression of D-type cyclins in AL amyloidosis plasma cells.
- Amyloid Deposits in the Bone Marrow of Patients with Amyloid Light Chain Amyloidosis Do Not Impact Stem Cell Mobilization or Engraftment.
- Multiple arterial and venous thromboembolic complications in AL amyloidosis and cardiac involvement: a case report and literature review.
- AL amyloidosis: who, what, when, why, and where.
- Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis.
- Immunoglobulin light chain, Blimp-1 and cytochrome P4501B1 peptides as potential vaccines for AL amyloidosis.
- Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study.
- Dysregulation of miRNAs in AL amyloidosis.
- Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients.
- Developmental and growth defects in mice with combined deficiency of CK2 catalytic genes.
- CK2α is essential for embryonic morphogenesis.
- Amyloidotic cardiomyopathy: multidisciplinary approach to diagnosis and treatment.
- Amyloidosis: pathogenesis and new therapeutic options.
- Myocardial infarction with "clean coronaries" caused by amyloid light-chain AL amyloidosis: a case report and literature review.
- Evidence for a functional role of the molecular chaperone clusterin in amyloidotic cardiomyopathy.
- Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis.
- Oral cyclic melphalan and dexamethasone for patients with AL amyloidosis.
- Role of glycosaminoglycan sulfation in the formation of immunoglobulin light chain amyloid oligomers and fibrils.
- The critical role of the constant region in thermal stability and aggregation of amyloidogenic immunoglobulin light chain.
- Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure.
- Impaired 3',5'-cyclic adenosine monophosphate-mediated signaling in immediate early responsive gene X-1-deficient vascular smooth muscle cells.
- Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis.
- Amyloidogenic light chains induce cardiomyocyte conTractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway.
- Dynamic expression of a LEF-EGFP Wnt reporter in mouse development and Cancer.
- Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis.
- Threonine 393 of beta-catenin regulates interaction with Axin.
- AL-Base: a visual platform Analysis tool for the study of amyloidogenic immunoglobulin light chain sequences.
- Loss of AND-34/BCAR3 expression in mice results in rupture of the adult lens.
- Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid depo...
- Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue.
- The alpha catalytic subunit of protein kinase CK2 is required for mouse embryonic development.
- Green tea polyphenols reverse cooperation between c-Rel and CK2 that induces the aryl hydrocarbon receptor, slug, and an invasive phenotype.
- Heterogeneity in primary structure, post-translational modifications, and germline gene usage of nine full-length amyloidogenic kappa1 immunoglobulin light chains.
- An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis.
- Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation.
- Soft tissue, joint, and bone manifestations of AL amyloidosis: clinical presentation, molecular features, and survival.
- Association of acquired von Willebrand syndrome with AL amyloidosis.
- Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial.
- Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65.
- The A2B adenosine receptor protects against inflammation and excessive vascular adhesion.
- Inducible IkappaB kinase/IkappaB kinase epsilon expression is induced by CK2 and promotes aberrant nuclear factor-kappaB activation in breast Cancer cells.
- Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosis.
- RelB/p52 NF-kappaB complexes rescue an early delay in mammary gland development in transgenic mice with targeted superrepressor IkappaB-alpha expression and promote ca...
- Kinase-inactive glycogen synthase kinase 3beta promotes Wnt signaling and mammary tumorigenesis.
- Oncogenic signaling pathways activated in DMBA-induced mouse mammary Tumors.
- Xth International Symposium on Amyloid and Amyloidosis April 18-22, 2004 (selected highlights) Tours, Loire Valley, France.
- Protein kinase CK2 is required for dorsal axis formation in Xenopus embryos.
- Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation.
- High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study.
- Persistent pleural effusions in primary systemic amyloidosis: etiology and prognosis.
- Mouse mammary tumor virus c-rel transgenic mice develop mammary Tumors.
- CK2 phosphorylation of the armadillo repeat region of beta-catenin potentiates Wnt signaling.
- Incidence and outcome of Acute renal failure complicating autologous stem cell transplantation for AL amyloidosis.
- T1alpha, a Lung type I cell differentiation gene, is required for normal Lung cell proliferation and alveolus formation at birth.
- High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal Disease.
- Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis.
- Diagnosis and treatment of Al amyloidosis.
- Protein kinase CK2 promotes aberrant activation of nuclear factor-kappaB, transformed phenotype, and survival of breast Cancer cells.
- Pathway pathology: histological differences between ErbB/Ras and Wnt pathway transgenic mammary Tumors.
- AL amyloidosis, a curable Disease?
- Induced Pluripotent Stem Cell Modeling of Multisystemic, Hereditary Transthyretin Amyloidosis.
- First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction.
Schools
Harvard Medical School
Brigham and Women39s Hospital
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Bladder Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Assurant Health
- Blue Card PPO
- BlueConnect HMO
- Blue with Managed Care Behavioral Health HMO
- Preferred Blue PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- Commercial Insurance Company
- Emblem Health
- First Health (Coventry Health Care) PPO
- Humana
- Kaiser Permanente
- Medicare MCR
- MultiPlan PPO
- MVP Health Care
- Neighborhood Health Plan
- POMCO Group
- Priority Health
- Tricare
- Tufts Health Plans
- Tufts PPO
- UniCare
- United Healthcare
Awards
- Elected Member
- Super Doctor
Education
-
Brigham and Women's Hospital -
Harvard Medical School
Hospital
-
Boston Medical Center
Drug Facts
| NPI NUMBER | 1457322588 | |
| NPPES Provider LastName | SELDIN | |
| NPPES Provider FirstName | DAVID | |
| NPPES Provider ZIPCode | 021182905 | |
| NPPES Provider State | MA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 17.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1457322588 |
| Last Name Of The Provider | SELDIN |
| First Name Of The Provider | DAVID |
| View All |
Similar Doctors
|
|
Dr. Ryan B. Corcoran, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lilli M. Petruzzelli, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kevin J. Cheung, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Julie-Aurore Losman, MD |
|
|
Dr. Jennifer A. Ligibel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Leif W. Ellisen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jean M. Connors, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Yeowon A. Kim, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anna F. Farago, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bradley W. Blaser, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel G. Tenen, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Ayad Hamdan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jens G. Lohr, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christina I. Herold, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lecia V. Sequist, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Murray M. Bern, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen W. Louie, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kellie Sprague, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marjory Charlot, MD
This Doctor is OpenDoctor Recommended.
|